New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
17:22 EDTOMEROmeros down after trial does not meet all endpoints
"We are pleased with the outcome of this trial," said Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "While not meeting all endpoints, the consistently positive results on pain reduction and the series of related inflammatory measures mark a clear path to approval of OMS103HP. The arthroscopy market is large and these data, together with an early 2013 NDA submission for our ophthalmic surgery product OMS302, set the stage for potentially two near-term market launches."
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 20, 2014
07:16 EDTOMERAmerican Academy of Ophthalmology to hold annual meeting
AAO Annual Meeting 2014 is being held in Chicago on October 18-21.
October 7, 2014
07:06 EDTOMEROmeros, Hospira enter into commercial suply agreement for Omidria
Omeros Corporation (OMER) said in a filing that on October 3, it, Hospira S.p.A. and Hospira Worldwide, Inc. (HSP) entered into a Commercial Supply Agreement, pursuant to which Hospira will act as a non-exclusive supplier of Omerosí product Omidria for commercial sale in the United States and the European Union. Pursuant to the Supply Agreement, Hospira has agreed to manufacture and supply, and Omeros has agreed to purchase, a minimum percentage of Omerosí requirements of Omidria for commercial sales and clinical supplies for the development of additional therapeutic indications in the United States. In addition, upon receipt of marketing approval in the EU, Hospira has agreed to manufacture and supply a portion of Omerosí requirements of Omidria in the EU in an amount to be mutually agreed by the parties within four months of marketing approval in Europe, with there being no minimum purchase and supply requirement in the EU if the parties do not reach agreement during such time period and the agreement is not amended thereafter. The Supply Agreement obligates Omeros to provide to Hospira a rolling, non-binding long-term forecast of Omerosí estimated required quantities of Omidria. The Supply Agreement has an initial term of five years from the date of first commercial sale of Omidria in any country in the Territory. Upon termination of the Supply Agreement, except in the case of termination for an uncured breach by Hospira, Omeros will be required to purchase all of Hospiraís inventory of Omidria and, if applicable, work in progress and reimburse Hospira for all supplies purchased or ordered based on firm purchase orders or Omerosí estimates of its requirements of Omidria.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use